Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences:
https://mma.prnewswire.com/media/2646316/Edgewise_Therapeutics_Logo.jpg
Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside chat:Tuesday, November 11, 2025 at 8:30 am ET
Piper Sandler 37th Annual Healthcare ConferenceFireside chat:Tuesday, December 2, 2025 at 2 pm ET
8th Annual Evercore Healthcare ConferenceFireside chat:Wednesday, December 3, 2025 at 3:25 pm ET
The webcasts can be found on the Edgewise Events & Presentations pageand will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:www.edgewisetx.comor follow us onLinkedIn,X,FacebookandInstagram.
https://edge.prnewswire.com/c/img/favicon.png?sn=LA18101&sd=2025-11-07
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-participate-in-upcoming-investor-conferences-302607782.html
SOURCE Edgewise Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=LA18101&Transmission_Id=202511070800PR_NEWS_USPR_____LA18101&DateId=20251107